After several notable moves to grow the reach of its biomanufacturing platform in recent months, Antheia is linking arms with ...

Just a few months after Boehringer Ingelheim broke into the oncology space with the first drug that can target a rare tumor ...

The first of seven challenges for which Teva is seeking novel solutions revolves around human-predictive platforms for ...

The new plant will allow the company to execute end-to-end clinical- and commercial-stage production of its mRNA medicines.

Facing the fact that Lundbeck’s unexpected offer for Avadel was sweeter, Alkermes has come back to the negotiating table with ...

Two months after Celltrion bought a U.S. manufacturing facility from Eli Lilly for roughly $330 million, the South Korean ...

In its mission to grow the reach of its pyruvate kinase (PK) activator Pyrukynd (mitapivat), Agios Pharmaceuticals has come up short of producing an unequivocal win in the key indication of sickle | ...

Amid the pharma industry's breakneck onshoring push this past year, North Carolina has been a major beneficiary as investment announcements rolled in from the likes of ...

When Ali Sullivan enrolled at Indiana University, she thought she wanted to become a speech pathologist. Midway through her ...

Now, more than half a year later, the expansion plan for one of the company’s new facilities—a former magazine plant in ...

Novo revealed Monday that the self-pay cost for the two lowest dosages of Wegovy and Ozempic will be $349 per month, down ...

With a fresh FDA endorsement for its drug plozasiran, California-based Arrowhead Pharmaceuticals has successfully broken ...